Effects of Recombinant Interferon-Gamma and Interleukin-2 on the Generation of Lymphokine-Activated Killer Cells in Vitro

References

• Grimm E A, Mazumder A, Zhang H T, et al. The lymphokine activated killer cell phenomenon: lysis of NK resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823–1841
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Mule J J. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2. Surgery 1985; 98(3)437–444
   PubMed Web of Science ®Google Scholar
• Weigent D A, Stanton G J, Johnson H M. Interleukin 2 enhances natural killer cell activity through induction of gamma interferon. Infect Immun 1983; 41: 992
   PubMed Web of Science ®Google Scholar
• Daugherty J P, Weiner L M. Augmentation of IL-2 induced IL-2 receptor expression by IFN-gamma. Proc AACR 1987; 28: 341, (Abstr 1351)
   Google Scholar
• Abdel-Mageed A, Findley H W, Franco C, et al. Natural killer cells in children with acute leukemia. The effect of interleukin-2. Cancer 1987; 60: 2913–2918
   PubMed Web of Science ®Google Scholar
• Pross H F, Baines M G, Rubin P, et al. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. Quantitation of natural killer (NK) cell activity. J Clin Immunol 1981; 1: 51
   PubMed Web of Science ®Google Scholar
• Lanier L L, Le A M, Civin C I, et al. The relationship of CD 16 (Leu 11) and Leu 19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986; 136(12)4480–4486
   PubMed Web of Science ®Google Scholar
• Phillips J H, Lanier L L. Dissection of the lymphokine-activated killer phenomenon: Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986; 164: 814–825
   PubMed Web of Science ®Google Scholar
• Zarcone D, Prasthofer E F, Malavasi F, et al. Ultrastructural analysis of human natural killer cell activation. Blood 1987; 69: 1725–1736
   PubMed Web of Science ®Google Scholar
• Sverdersky L, Shepard H M, Spencer S A, et al. Augmentation of human natural cell-mediated cytotoxicity by recombinant human interleukin-2. J Immunol 1984; 133: 714
   PubMed Web of Science ®Google Scholar
• Brunda M J, Davatelis V. Augmentation of natural killer cell activity by recombinant interleukin-2 and recombinant interferons. Mechanisms of Cytotoxicity by NK Cells, R B Herberman, D M Callawaert. Academic Press, Orlando, FL 1985; 397
   Google Scholar
• Lotzova E, Savary C A, Gutterman J U, et al. Modulation of natural killer cell-mediated cytotoxicity by partially purified and cloned interferon-alpha. Cancer Res 1982; 42: 2480
   PubMed Web of Science ®Google Scholar
• Abbud-Filho M, Ransil B J, Kelley V E, et al. Natural killer cell response to interferons. Clin Immunol Immunopathol 1986; 39: 264–276
   PubMedGoogle Scholar
• Itoh K, Shiba K, Shimizu Y, Suzuki S, Kumagai K. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL-2) in collaboration with interferon-gamma (IFN-gamma). J Immunol 1985; 134: 3124
   PubMed Web of Science ®Google Scholar
• Ochoa A C, Gromo G, Alter B J, et al. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL1, interferon-gamma and -beta-1. J Immunol 1987; 138: 2728–2733
   PubMed Web of Science ®Google Scholar
• Brunda M J, Tarnowski D, Davatelis V. Interaction of recombinant interferons with recombinant interleukin-2: Differential effects on natural killer cell activity and interleukin-2 activated killer cells. Int J Cancer 1986; 37: 787
   PubMed Web of Science ®Google Scholar
• Sayers T J, Mason A T, Ortaldo J R. Regulation of human natural killer cell activity by interferon-alpha: Lack of a role in interleukin-2 mediated augmentation. J Immunol 1986; 136: 2176
   PubMed Web of Science ®Google Scholar
• Rook A H, Hooks J J, Quimman G V, et al. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through an interferon-independent mechanism. J Immunol 1985; 134: 3124–3129
   PubMedGoogle Scholar
• Sone S, Utsugi T, Nii A, Ogura T. Differential effects of recombinant interferons alpha, beta and gamma on induction of human lymphokine (IL-2)-activated killer activity. J Natl Cancer Inst 1988; 80: 425
   PubMed Web of Science ®Google Scholar
• Braakman E, Van Tunen A, Meager A, Lucas C J. IL-2 and IFN-gamma enhanced natural cytotoxic activity: analysis of the role of different lymphoid subsets and implications for activation routes. Cell Immunol 1986; 99: 476–488
   PubMed Web of Science ®Google Scholar
• Shiiba K, Suzuki R, Kàwakami K, Ohuchi A, Kumagai K. Interleukin 2-activated killer cells: generation in collaboration with interferon-gamma and its suppression in cancer patients. Cancer Immunol Immunother 1986; 21: 119–128
   PubMed Web of Science ®Google Scholar
• Herberman R B, Holden H T, Djeu J Y, et al. Macrophages as regulators of immune responses against tumors. Adv Exp Med Biol 1980; 121B: 361
   Google Scholar
• Koren H S, Leung K H. Modulation of human NK cells by interferon and prostaglandin E1. Mol Immunol 1982; 19: 1341
   PubMed Web of Science ®Google Scholar
• Piontek G E, Taniguchi K, Ljunggren A, Gronberg R, Kiessling G, Klein K Karre. YAK-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. J Immunol 4281; 135
   Google Scholar
• DeFries R U, Golub S H. Characteristics of mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells. J Immunol 1988; 140: 3686–3693
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Kimmig A, Lang P, et al. Interferon-gamma up-regulates the susceptibility of human neuroblastoma cells to interleukin 2-activated natural killer cells. Nat Immun Cell Growth Reg, in press
   PubMedGoogle Scholar
• Powell J, Stone J, Chan W C, et al. Interferon-gamma treated K562 target cells distinguish NK from LAK cells. Cell Immunol 1989; 118: 250–264
   PubMed Web of Science ®Google Scholar
• Tsudo M, Goldman C K, Bongiovanni K F, et al. The p75 peptide is the receptor for interleukin-2 expressed on large granular lymphocytes and is responsible for me interleukin-2 activation of these cells. Proc Natl Acad Sci (USA) 1987; 84: 5394–5398
   PubMed Web of Science ®Google Scholar
• Lotze M T, Matory Y L, Ettinghausen S E, et al. In vivo administration of purified human interleukin 2. n. Half life, immunologic effects and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 1985; 135: 2865–2875
   PubMed Web of Science ®Google Scholar